- Home
- LVS vs ONC Comparison
LVS vs ONC Comparison
Compare LVS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVS
- ONC
- Stock Information
- Founded
- LVS 1988
- ONC 2010
- Country
- LVS United States
- ONC Switzerland
- Employees
- LVS N/A
- ONC N/A
- Industry
- LVS Hotels/Resorts
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- LVS Consumer Discretionary
- ONC Health Care
- Exchange
- LVS Nasdaq
- ONC Nasdaq
- Market Cap
- LVS 27.1B
- ONC 26.9B
- IPO Year
- LVS 2004
- ONC N/A
- Fundamental
- Price
- LVS $48.22
- ONC $245.49
- Analyst Decision
- LVS Buy
- ONC Strong Buy
- Analyst Count
- LVS 13
- ONC 9
- Target Price
- LVS $55.83
- ONC $325.56
- AVG Volume (30 Days)
- LVS 4.8M
- ONC 367.8K
- Earning Date
- LVS 07-23-2025
- ONC 08-06-2025
- Dividend Yield
- LVS 2.07%
- ONC N/A
- EPS Growth
- LVS N/A
- ONC N/A
- EPS
- LVS 1.78
- ONC N/A
- Revenue
- LVS $11,201,000,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- LVS $5.15
- ONC $869.15
- Revenue Next Year
- LVS $5.95
- ONC $19.07
- P/E Ratio
- LVS $27.03
- ONC N/A
- Revenue Growth
- LVS N/A
- ONC 51.16
- 52 Week Low
- LVS $30.18
- ONC $142.00
- 52 Week High
- LVS $56.61
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- LVS 74.15
- ONC N/A
- Support Level
- LVS $43.20
- ONC N/A
- Resistance Level
- LVS $44.41
- ONC N/A
- Average True Range (ATR)
- LVS 1.13
- ONC 0.00
- MACD
- LVS 0.58
- ONC 0.00
- Stochastic Oscillator
- LVS 95.68
- ONC 0.00
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.